By Darrin LaVelle, Founder of RENVA Health
Last updated: July 3, 2026
Short answer: appetite changes can start within days to a couple of weeks, but clinically meaningful weight loss (5% or more) typically takes 12 to 24 weeks to show up, and most people reach their maximum weight loss somewhere between 9 and 12 months of continuous treatment.
If you've started a GLP-1 medication or are about to, it helps to know what a realistic timeline actually looks like — not to manage expectations down, but because the trajectory is genuinely different from what a lot of people assume going in. This isn't a fast-acting drug in the way some people expect; it's a gradual process with a well-documented shape.
Before any meaningful weight loss shows up on a scale, the earliest effects are usually about appetite and fullness, not weight.
These early appetite effects tend to strengthen as the dose increases through the titration schedule — which is also when gastrointestinal side effects like nausea tend to cluster, since both are tied to the same increasing dose.
Across both semaglutide and tirzepatide trials, the overall shape of the weight loss curve follows a consistent pattern, even though the total amount of loss differs between the two drugs.
During the early titration period — when the dose is still being gradually increased toward the maintenance level — weight loss tends to be small, often in the range of 1–2% of starting body weight by around week 4. This is expected: at low starting doses, the appetite-suppressing effect hasn't reached its full strength yet.
This is generally where the most noticeable and rapid weight loss happens, as doses reach intermediate-to-maintenance levels. Most people cross the 5% weight-loss threshold — generally considered the point where a health benefit becomes clinically meaningful — somewhere in this window. In the tirzepatide trials specifically, roughly three-quarters of a person's eventual total weight loss was typically achieved by around week 40.
Weight loss continues during this phase but at a decelerating pace, as the body's energy balance shifts toward a new equilibrium. For semaglutide, trial data suggests the lowest point (the "nadir") of weight tends to occur around week 36, with a gradual flattening afterward. For tirzepatide, time-to-plateau analyses put the median around 36 to 52 weeks depending on the dose.
Once someone reaches this stage, weight typically stabilizes with only small fluctuations. This plateau isn't a sign that the medication has "stopped working" — it's an expected pharmacological outcome as the body adapts to the new appetite and energy balance the medication has created. It's a stable state, not a failure state.
One of the more useful things the research shows is that weight loss correlates more strongly with cumulative dose and time at maintenance level than with time since starting the medication overall. In practice, this means the titration period — those first several weeks at low doses — isn't wasted time, but it also isn't representative of what the medication will eventually do. The real effect depends on reaching, and staying at, an effective maintenance dose.
Titration schedules are built deliberately slow for a reason. Semaglutide typically starts at 0.25 mg weekly, and tirzepatide at 2.5 mg weekly — both a fraction of the eventual maintenance dose. This isn't caution for its own sake: starting low and increasing gradually is specifically designed to reduce gastrointestinal side effects while the body adjusts, which is also why appetite suppression is muted at first. Most people don't experience the medication's full appetite-suppressing effect until they reach an intermediate dose — generally around 1.0–1.7 mg weekly for semaglutide or 7.5–10 mg weekly for tirzepatide — which for most people lands somewhere around weeks 8 to 12.
It's worth being upfront about something that often gets glossed over: a meaningful minority of people don't respond strongly to these medications, even with correct dosing and adherence.
One multicenter study of GLP-1 medications for obesity broke down responses at 6–12 months into three groups:
Other reviews describe a similar range, generally citing that 10–20% of patients don't reach the 5% threshold that's typically considered clinically meaningful, despite proper dosing. Researchers are actively investigating why — early evidence points to genetic factors and individual differences in gut hormone signaling as part of the explanation, sometimes referred to as GLP-1 "resistance." If you've been on a proper dose for several months without meaningful results, that's a real, documented pattern — not necessarily something you're doing wrong — and it's worth raising directly with your prescriber, since alternative approaches may be more effective for you specifically.
Research has identified some patterns in who tends to see faster or larger average results, though none of these predict any individual's outcome with certainty:
Associated with stronger response:
Associated with more modest response:
Research has also found some consistent differences by sex: one meta-analysis found women lost more weight on average than men (around 10.9% versus 6.8%), while cardiometabolic benefits like improved blood pressure and cholesterol were similar across both groups. The same body of research found women experience persistent nausea and vomiting at higher rates than men — a pattern researchers think may be connected to differences in how estrogen interacts with GLP-1 signaling, though this is still an active area of study.
If you're a few weeks into treatment and don't yet see meaningful changes on the scale, that's consistent with how these medications are documented to work — not necessarily a sign that something is wrong. The appetite changes usually arrive first, the visible weight loss follows over months, and the full effect generally takes the better part of a year to fully play out. Patience during the titration period specifically is part of how these medications are designed to work, since the schedule is built to minimize side effects on the way to an effective dose — not to delay results unnecessarily.
If you're several months into a maintenance dose without meaningful loss, that's a different situation worth discussing directly with your prescriber, since a real subset of people genuinely don't respond as strongly to a given medication, and there may be other options worth considering.
Q: How soon will I feel less hungry after starting?
Many people notice earlier fullness and smaller natural portions within the first one to two weeks, even at the lowest starting dose.
Q: When will I actually start losing visible weight?
Meaningful weight loss (5% or more of starting weight) typically shows up between 12 and 24 weeks for most people, though timing varies by individual and by which medication you're on.
Q: When does weight loss plateau?
Most people reach their maximum or near-maximum weight loss between roughly 9 and 12 months of continuous treatment, after which weight tends to stabilize.
Q: What if I've been on the medication for months with no results?
Somewhere between 10–20% of people don't reach clinically meaningful weight loss even with proper dosing — this is a documented pattern, not necessarily a personal failure. Talk to your prescriber about next steps if this describes your experience.
Q: Does the plateau mean the medication has stopped working?
No — plateau is an expected outcome as your body reaches a new energy balance, not a sign the medication has lost effectiveness.
See also: What Happens If You Stop Taking GLP-1 Medications? for what the research shows about long-term maintenance, and GLP-1 Side Effects for what to expect during the dose escalation period specifically.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizGLP-1 medications explained in plain language: what they are, how they work in your gut and brain, and what the research shows about weight loss results.
Research on stopping GLP-1 medications shows most people regain a significant share of lost weight. Here's what the data actually shows and why it happens.
Tirzepatide activates one more hormone receptor than semaglutide — and across every major trial, that difference shows up as more average weight loss.